Abstract
Mr. A is 32 years old. He was diagnosed with ulcerative colitis at the age 19 and is managed with five ASAs. He sees his IBD specialist on a yearly basis. His last colonoscopy was 3 years ago. At his last appointment, he was found to have abnormal liver biochemistry (bilirubin 23, alkaline phosphatase (ALP) 243, ALT 65, AST 72, gamma glutamyl transpeptidase (GGT) 145, albumin 36). He describes fatigue but is otherwise well. You suspect he may have PSC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382:1587–99.
Eaton JE, Talkwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521–36.
Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun. 2016;66:25–39.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.
Guma M, Firestein GS. IgG4 related diseases. Best Pract Res Clin Rheumatol. 2012;26:425–38.
Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901–10.
Lindor KD, Kowdley KV, Luketic VA, et al. High dose ursodeoxycholic acid for the treatment of sclerosing cholangitis. Hepatology. 2009;50:808–14.
Hansen JD, Kumar S, Lo W-K, et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2013;58:3079–87.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis – AASLD practice guidelines. Hepatology. 2014;51:660–78.
Ponsioen C, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrumpf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis; review and results from an international PSC study group consensus process. Hepatology. 2016;63(4):1357–67.
Ravikumar R, Tsochatzis E, Jose S, Allison M, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63:1139–46.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Corrigan, M., Ferguson, J. (2017). Primary Sclerosing Cholangitis. In: Cross, T. (eds) Liver Disease in Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-43126-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-43126-0_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43125-3
Online ISBN: 978-3-319-43126-0
eBook Packages: MedicineMedicine (R0)